The Great Scale-Up: How Cell & Gene Therapy Manufacturing Is Being Industrialized in 2026

 Cell and gene therapies have crossed a threshold: they are no longer defined solely by scientific novelty. They are being judged-by regulators, payers, clinicians, and patients-on reliability, reproducibility, and delivery at scale.

That shift is reshaping the Cell & Gene Therapy (CGT) Manufacturing Services landscape. “Can we make it?” has evolved into “Can we make it consistently, compliantly, and fast enough to meet real-world demand-without breaking the cost model?”

For CDMOs, this is a pivotal moment. For therapy developers, it’s an opportunity to lock in manufacturing strategies that reduce risk and shorten time-to-commercialization. For everyone across the supply chain, it’s a call to industrialize.

Below is a practical look at what’s trending right now in CGT manufacturing services-and what it means for decision-makers who need to scale from early clinical to commercial reality.

The trending topic: The industrialization of CGT manufacturing

Industrialization is not a single technology or a one-time facility upgrade. It’s a mindset and an operating system that prioritizes:

• Platform processes over bespoke workflows
• Closed, automated systems over open, manual operations
• Real-time monitoring over end-of-run surprises
• Quality-by-design over quality-by-inspection
• Supply chain robustness over heroics

Why is this trending now? Because the sector is maturing under pressure:

1. More programs are reaching later-stage development, where comparability expectations, control strategies, and capacity planning become non-negotiable.
2. The industry is experiencing a “make-or-break” moment on cost and reliability, especially for patient-specific workflows.
3. Regulatory expectations for control, traceability, and lifecycle management are rising, particularly as developers move into multi-site networks.

Industrialization is how the industry moves from pioneering to performing.

What industrialization looks like in manufacturing services today

1) Platforming the process: fewer custom builds, more configurable “recipes”

Historically, many CGT processes were built around the biology of a single program. That approach is slow, expensive, and fragile.

The trend is toward platform manufacturing-not “one size fits all,” but a common backbone that can be configured:

• Standardized upstream and downstream unit operations where possible
• Repeatable closed processing steps
• Modular analytics packages
• Reusable validation and documentation frameworks

For therapy developers, platform alignment can reduce tech transfer friction and accelerate readiness for scale.

For CDMOs, platforming improves scheduling efficiency, training consistency, and deviation reduction.

2) Closed and automated operations are becoming a business requirement

Closed systems are no longer just a contamination-control strategy. They are becoming an economic strategy.

Why? Because they can reduce:

• Cleanroom classification burdens for certain steps
• Operator interventions that create variability
• Batch-to-batch risk from manual handling
• Turnaround time driven by lengthy room clearance and gowning constraints

Automation adds another layer: it turns “operator skill” into “process execution,” which is essential for scaling a network and maintaining comparability.

The operational payoff is clear: the more you can close and automate, the more predictable your capacity becomes.

3) Analytics and control strategies are shifting left

In CGT, traditional end-product testing alone rarely provides the confidence needed for consistent release-especially when timelines are tight and products are living systems.

Industrialization pushes analytics earlier and deeper:

• More in-process controls to catch drift before it becomes failure
• Stronger linkage between CQAs, CPPs, and raw material attributes
• Increasing use of rapid methods where scientifically justified
• Greater emphasis on sample management, chain-of-custody, and data integrity

For manufacturing services, the differentiator isn’t only which instruments are in the lab. It’s the control strategy design, the operational discipline, and the data usability across the batch record.

4) Digital thread and data integrity: from “documentation” to “decision-making”

As therapies move across sites, scales, and partners, documentation becomes a velocity constraint if it remains manual and fragmented.

The trend is toward a stronger digital thread:

• Electronic batch records and structured data capture
• Digital chain-of-identity and chain-of-custody integration
• Equipment connectivity and audit-ready logs
• Faster deviation triage through better context and traceability

This matters for developers because comparability and lifecycle changes are easier to defend when data is consistent and accessible.

It matters for CDMOs because operational excellence becomes measurable-and scalable.

5) Raw materials and supply chain control are now core to manufacturing success

In CGT, small changes in raw materials can produce outsized impacts. And even when the process is perfect, missing a single critical item can stop production.

Industrialization means treating supply chain as part of the process:

• Dual sourcing plans for critical materials
• Robust material qualification and change notification pathways
• Strong vendor management and incoming inspection strategies
• Clear definitions of “critical” versus “non-critical” components

In services, the most valuable partners increasingly act like supply chain co-architects, not just manufacturers.

6) Facility strategy is becoming modular and networked

Traditional scale-up logic (“bigger tanks, bigger suites”) does not map cleanly onto many CGT products.

Instead, the facility trend is:

• Modular, replicable cleanroom “pods”
• Multi-product flexibility with segregation-by-design
• Parallel processing and scheduling optimization
• Network approaches across sites to manage demand and risk

For autologous therapies, industrialization often looks like scaling out (more identical manufacturing lines).

For viral vectors and certain gene therapies, it may still involve scaling up-but with a stronger focus on standardization, throughput, and yield predictability.

The uncomfortable truth: industrialization forces hard choices

Industrialization is not purely additive. It requires tradeoffs and decisions that many teams delay.

Choice 1: Speed now vs. sustainability later

Bespoke processes can move quickly early on. But every custom step becomes technical debt at late stage. Teams must decide when to pay it down.

Choice 2: “Best possible yield” vs. “most reliable yield”

Some process optimizations increase peak yield but also increase variability and failure rates. Industrial manufacturing prioritizes the yield you can reproduce-batch after batch.

Choice 3: “We can manage it manually” vs. “We need a system”

Manual operations can work in small volumes. But manual operations do not scale linearly-headcount, training, and deviations grow faster than throughput.

What therapy developers should ask manufacturing service partners in 2026

Selecting a CGT manufacturing services partner is no longer just a capacity decision. It’s an industrialization decision.

Here are questions that reveal whether a partner can support the next phase-not just the next batch:

1. How much of your process is truly platformed? Ask what is standardized (materials, equipment, analytics, documentation) and what changes program-to-program.

2. Where are operations closed, and where are they still open? Look for a clear rationale-and a roadmap to reduce open interventions.

3. How do you manage comparability across scale, site, or equipment changes? The answer should include strategy, data expectations, and governance, not just “we’ve done it before.”

4. What does your deviation profile look like, and how do you trend it? You’re not looking for “zero deviations.” You’re looking for mature investigations, recurrence prevention, and transparency.

5. How do you qualify and manage raw materials across the product lifecycle? Focus on change management, vendor oversight, and continuity planning.

6. How will data flow from manufacturing to QA to release decisions? Ask about batch record structure, audit trails, and how quickly the team can retrieve critical information.

7. What is your strategy for workforce training and operator qualification? Industrialization depends on repeatable execution. Training cannot be informal.

What CDMOs need to win in an industrializing market

As industrialization becomes the new benchmark, manufacturing service providers differentiate less by “we can do it” and more by “we can do it predictably.”

Three strategic priorities stand out:

1) Build the “operating system,” not just the facility

Expanding cleanroom space without standardizing execution simply creates more places where variability can happen.

Investments that support industrialization include:

• Standard work and disciplined execution models
• Strong technology transfer playbooks
• QA/Operations alignment that enables speed with control
• Digital batch records and structured data practices

2) Make tech transfer a product, not a project

Tech transfer is often where timelines slip and costs balloon.

Leading organizations treat transfer as a repeatable capability:

• Clear templates for process descriptions and risk assessments
• Defined readiness gates
• Cross-functional teams trained to anticipate common failure points
• Practical comparability planning

3) Offer end-to-end thinking, even when services are modular

Even if a client buys only one segment (e.g., viral vector, cell processing, fill-finish, testing), the best partners help teams understand end-to-end implications.

Industrialization rewards CDMOs who connect the dots:

• Upstream changes and downstream consequences
• Manufacturing choices that affect release and stability
• Raw material decisions that affect process performance

Where this trend goes next

Industrialization in CGT manufacturing services is still early. But its trajectory is clear.

Over the next phase, expect increasing emphasis on:

• Scalable closed-system architectures that reduce variability and enable multi-site replication
• Faster, more informative analytics that support real-time decisions and stronger control strategies
• Data-centered QA that accelerates release while strengthening inspection readiness
• Facility models designed for throughput and replication, not just expansion

The winners-both developers and CDMOs-will be those who treat manufacturing as a strategic product capability, not a downstream task.

Because in CGT, the science can change a life. But only manufacturing can deliver it-reliably, repeatedly, and at the scale patients need.

If your organization is making manufacturing decisions this year, the most important question may be this:

Are you building for the next clinical run-or for the first commercial year? 

Explore Comprehensive Market Analysis of Cell & Gene Therapy Manufacturing Services Market 

Source -@360iResearch